Sofosbuvir/velpatasvir plus ribavirin for Child-Pugh B and Child-Pugh C hepatitis C virus-related cirrhosis.

doi:10.3350/cmh.2021.0155

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Sofosbuvir/velpatasvir plus ribavirin for Child-Pugh B and Child-Pugh C hepatitis C virus-related cirrhosis.

Clinical and molecular hepatology - 1 Oct 2021

Liu Chen-Hua, Chen Chi-Yi, Su Wei-Wen, Liu Chun-Jen, Lo Ching-Chu, Huang Ke-Jhang, Chen Jyh-Jou, Tseng Kuo-Chih, Chang Chi-Yang, Peng Cheng-Yuan, Shih Yu-Lueng, Huang Chia-Sheng, Kao Wei-Yu, Yang Sheng-Shun, Tsai Ming-Chang, Wu Jo-Hsuan, Chen Po-Yueh, Su Pei-Yuan, Hwang Jow-Jyh, Fang Yu-Jen, Lee Pei-Lun, Tseng Chi-Wei, Lee Fu-Jen, Lai Hsueh-Chou, Hsieh Tsai-Yuan, Chang Chun-Chao, Chang Chung-Hsin, Huang Yi-Jie, Kao Jia-Horng

Abstract excerpt

BACKGROUND/AIMS: Real-world studies assessing the effectiveness and safety of sofosbuvir/velpatasvir (SOF/VEL) plus ribavirin (RBV) for Child-Pugh B/C hepatitis C virus (HCV)-related cirrhosis are limited. METHODS: We included 107 patients with Child-Pugh B/C HCV-related cirrhosis receiving SOF/VEL plus RBV for 12 weeks in Taiwan. The sustained virologic response rates at off-treatment week 12 (SVR12) for the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antiviral Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carbamates

Share to Hepatitis C

Share to Hepatitis C, Chronic

Share to Heterocyclic Compounds, 4 or More Rings

Share to Liver Cirrhosis

Share to Ribavirin

Share to Sofosbuvir

Source

Open in PubMed Open full text

Identifiers

PMID: 34255961
DOI: 10.3350/cmh.2021.0155
PMCID: PMC8524072

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Sofosbuvir/velpatasvir plus ribavirin for Child-Pugh B and Child-Pugh C hepatitis C virus-related cirrhosis.PMID 34255961Read ↗

Real-world clinical outcomes of sofosbuvir and velpatasvir treatment in HCV genotype 1- and 2-infected patients with decompensated cirrhosis: A nationwide multicenter study by the Japanese Red Cross Liver Study Group.Semantic proximity Read ↗

Sofosbuvir/velpatasvir for patients with chronic hepatitis C virus infection and compensated liver disease: real-world data in Taiwan.Semantic proximity Read ↗

Sofosbuvir and Velpatasvir for HCV in Patients with Decompensated Cirrhosis.Semantic proximity Read ↗

Efficacy and safety of sofosbuvir-velpatasvir with or without ribavirin in HCV-infected Japanese patients with decompensated cirrhosis: an open-label phase 3 trial.Semantic proximity Read ↗

Real-World Efficacy and Safety of Sofosbuvir/Velpatasvir/Voxilaprevir in Treatment Naive and Experienced Chronic Hepatitis C Patients: A Single-Center ExperienceSemantic proximity Read ↗

Efficacy of Sofosbuvir, Velpatasvir, and GS-9857 in Patients With Genotype 1 Hepatitis C Virus Infection in an Open-Label, Phase 2 Trial.Semantic proximity Read ↗

[Twelve-week of sofosbuvir/velpatasvir therapeutic regimen for chronic hepatitis C patients in northwest region of China: a real-world multicenter clinical study].Semantic proximity Read ↗

[A real-world study of the efficacy and safety of sofosbuvir and velpatasvir in the treatment of HCV-infected patients in a county in northern China].Semantic proximity Read ↗

The combination of simeprevir and sofosbuvir is more effective than that of peginterferon, ribavirin, and sofosbuvir for patients with hepatitis C-related Child's class A cirrhosis.Semantic proximity Read ↗

Efficacy of Sofosbuvir, Velpatasvir, and GS-9857 in Patients With Hepatitis C Virus Genotype 2, 3, 4, or 6 Infections in an Open-Label, Phase 2 Trial.Semantic proximity Read ↗

Real-world effectiveness and safety of sofosbuvir and nonstructural protein 5A inhibitors for chronic hepatitis C genotype 1, 2, 3, 4, or 6: a multicentre cohort study.Semantic proximity Read ↗

Safety and efficacy of sofosbuvir plus velpatasvir with or without ribavirin for chronic hepatitis C virus infection: A systematic review and meta-analysis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.